XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.86 and traded as high as $3.20. XBiotech shares last traded at $3.17, with a volume of 28,527 shares traded.
XBiotech Stock Down 4.1%
The firm has a 50 day moving average price of $2.87 and a 200 day moving average price of $3.26. The stock has a market cap of $92.99 million, a P/E ratio of -2.36 and a beta of 0.98.
XBiotech (NASDAQ:XBIT - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.
Institutional Trading of XBiotech
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp raised its stake in XBiotech by 15.2% during the 4th quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock valued at $835,000 after purchasing an additional 27,909 shares during the period. Bank of New York Mellon Corp grew its holdings in XBiotech by 7.5% during the 4th quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company's stock valued at $360,000 after buying an additional 6,328 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in XBiotech by 15.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company's stock valued at $218,000 after buying an additional 8,918 shares in the last quarter. Deutsche Bank AG purchased a new position in XBiotech during the 4th quarter valued at approximately $120,000. Finally, Barclays PLC grew its holdings in XBiotech by 13.9% during the 4th quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after buying an additional 3,661 shares in the last quarter. Institutional investors own 55.70% of the company's stock.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Further Reading
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
